Fig. 1: Study flow diagram.
Includes all screened and randomized participants. Participants who received dose 1 but not dose 2 continued to be evaluated for safety and immunogenicity.
Fig. 1: Study flow diagram. | Nature Communications
Includes all screened and randomized participants. Participants who received dose 1 but not dose 2 continued to be evaluated for safety and immunogenicity.
